Lower srebp-1a and fasn expression levels suggest that SCGN primarily achieved its anti-obesity effects via reduced cholesterol production, while CGN appeared to have a different anti-obesity mechanism by showing elevated aco expression, which promotes peroxisomal β-oxidation of fatty acids. The gene discussed is KLK15; the disease is obesity disorder.